Clinical trial IPAX-1
A multi-centre, open-label, single-arm, dose-finding phase I/II study to evaluate safety, tolerability, dosing schedule, and preliminary efficacy of carrier-added 4-L-[131I]iodo-phenylalanine (131I-IPA), administered as single or repetitive injections in patients with recurrent glioblastoma multiforme (GBM), concomitantly to 2nd line external radiation therapy (XRT) - IPAX-1
Cancers | |
---|---|
Organ | Liver |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 1/2 |
Academic trial | Non |
Sponsor | Telix International Pty Ltd |
EudraCT Identifier | 2018-002262-39 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03849105 |
Inclusion criteria | *Previously confirmed histological diagnosis of glioblastoma, with current clinical or imaging evidence for recurrence *Interval since end of 1st line XRT superior or equal to 6 months*Amino acid-based molecular imaging indicating pathologically increas |
Last update |